Programme


Wednesday, 6 November

 10:00

Registration opens for individuals participants and for groups

 

Thursday, 7 November

   9:00
 19:30

Exhibition
   9:00 Breast cancer patient advocacy session  
Introductions and greatest challenges in meeting the needs of patients with advanced breast cancer (Chairs: S. Knox, IT - K.A. Sabelko, US - F. Cardoso, PT) 

 10:30 

Coffee break

 11:00 Breast cancer patient advocacy session
Challenges and guidelines in advanced breast cancer
(Chairs: D. “CJ” M. Corneliussen-James, US and M. Morand, AU)
 11:00 prIME Oncology Satellite symposium supported by Celgene Corporation
Innovation and differentiation:
Key components of successful strategies for management of advanced breast cancer
 
  • Welcome and introduction (A. Di Leo, IT)
  • Contemporary chemotherapy for advanced breast cancer (ABC): Have we hit a glass ceiling? 
    (A. Di Leo, IT)
  • Tailoring chemotherapy for selected breast cancer phenotypes: The scientific rationale 
    (G. Curigliano, IT)
  • Audience questions and faculty comments 
  • The current and potential future role of albumin-bound paclitaxel in ABC (J. Cortés, ES)
  • Audience questions and faculty comments 
  • Taking what we’ve learned from ABC into the neoadjuvant setting (M. Untch, DE)
  • Symposium pearls and concluding remarks (A. Di Leo, IT)
 Symposium faculty:

Angelo Di Leo, Istituto Toscano Tumori, Hospital of Prato, Prato, IT
Javier Cortés, Vall d’Hebron University Hospital, Barcelona, ES
Giuseppe Curigliano, European Institute of Oncology, Milan, IT
Michael Untch, Helios Klinikum Berlin-Buch, Berlin, DE
  

 12:30

Lunch

 13:30

Opening session (Chairs: F. Cardoso, PT - L. Norton, US)
 13:30 Opening and introduction (Chair: F. Cardoso, PT)
 
  • Welcome to Lisbon (N. Cabral, President of the Port of Lisbon, PT)
  • Keynote lecture
    A personal journal through advanced breast cancer (D. Fenech, MT)

 14:15

Major advances since ABC1 (Chair: E.P. Winer, US)
 
  • Advances in HER-positive advanced breast cancer (I.E. Krop, US
  • Advances in TN advanced breast cancer (G.W. Sledge, US)
  • Advances in endocrine therapy and endocrine resistance (M.J. Piccart, BE)
  • Advances in cytotoxic and other targeted therapy (J. Gligorov, FR)
  • Advances in imaging (N. Houssami, AU)
  • Discussion 

 16:15

Coffee break

 16:35

Best abstract presentations (Chair: F. Cardoso, PT)
 
  • Nursing and patient advocacy:
    The challenges in optimising care in patients with advanced breast cancer: Results of an international survey (S. McCutcheon, UK)   
  • Clinical issues:
    Overall survival and sequential treatment of patients with metastatic breast cancer treated by German office-based medical oncologists - Outcome data from the TMK Registry Group (N. Marschner, DE)
  • Clinical issues:
    Meta-analysis resolves the role of combination versus sequential chemotherapy for metastatic breast cancer (R. Dear, AU)
     
  • Basic and translational research
    What we know about primary metastatic breast cancer: Pathological characteristics and outcome over a 10-year period  (J. Barinoff, DE)

 17:30

ABC Award and Lecture: Deconstructing metastasis
(Chair: L. Norton, US - Awardee: J. Massagué, US)
 18:00 Breast cancer patient advocacy session
How can the ABC guidelines address global challenges? (Chairs: M. Mayer, US and S. Mertz, US)
 18:00 GlaxoSmithKline Satellite symposium
Integrating novel combinations into the sequencing of HER2-positive metastatic breast cancer treatment
 
  • Introduction
  • Progression beyond trastuzumab: Where are we now?
    (V. Guarneri, IT)
  • Biologic rationale and clinical evidence for using two anti-HER2 therapies with different modes of action (W. Janni, DE)
  • How to define the right sequence in the HER2-positive metastatic breast cancer scenario? Interactive case studies (E. Ciruelos, ES)
  • Discussion and closing remarks
 Symposium faculty

Valentina Guarneri, University of Padova, IRCSS, Padova, IT
Wolfgang Janni, University Hospital Ulm University of Ulm, Ulm, DE
Eva Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

  
 19:30 Welcome cocktail

 

Friday, 8 November

  9:00
19:30

Exhibition

  9:00

Inoperable locally advanced breast cancer (part I) (Chairs: F. Cardoso, PT - E.P. Winer, US)

 

  • The biology of locally advanced breast cancer: Inflammatory and non-inflammatory (F. Penault-Llorca, FR)
  • Epidemiology and geographic differences (E. Senkus-Konefka, PL) 
  • Systemic therapy: Optimal strategies and therapies (N. Harbeck, DE)
  • Discussion 

10:15

Coffee break

10:45

Inoperable locally  advanced breast cancer (part II) (Chairs: F. Cardoso, PT - E.P. Winer, US)
 
  • Radiotherapy: Best timing and techniques (C. Vrieling, CH)
  • Surgery: Challenges and opportunities (M.J. Cardoso, PT)
  • Discussion 

 11:40  

Specific populations (Chair: K. Gelmon, CA)

 
  • Metastatic male breast cancer (S.H. Giordano, US)
  • BRCA-related advanced breast cancer (P.A. Francis, AU)
  • Discussion 
 12:30 Survivorship in advanced breast cancer 
Panel discussion
(Chair: K. Redmond, CH; Panelists: L. Fallowfield, UK - E. Bergsten Nordström, IT - M. Mayer, US - O. Pagani, CH - A.H. Partridge, US and N. West, UK)
 13:00 Lunch and poster session (please see the list of poster presentations at the bottom of this page)
 14:00

Specific metastatic sites (Chairs: F. André, FR - H.S. Rugo, US)

 
  • Multidisciplinary approach to liver metastases (C.H. Barrios, BR)
  • Update on brain metastases management (N.U. Lin, US)
  • Optimal management of pleural effusions (B. Kaufman, IL)
  • Chest wall recurrences and cutaneous metastases (K.L. Blackwell, US)
  • Can specific sites of metastases be predicted and prevented? (L. van 't Veer, US)
  • Discussion 
 15:40      Special session (Chair: L. Norton, US)
 
  • The role of mathematical and computer modeling for metastases research (S.D. Merajver, US)
  • Discussion
 16:00 Coffee break
 16:30    Supportive and palliative care issues (Chairs: M.S. Aapro, CH and G.W. Sledge, US)
 
  • Optimal pain control (L. Biganzoli, IT)
  • Optimal management of nausea and vomiting (J. Bergh, SE)
  • Psycological support: When and how? (L. Fallowfield, UK)
  • Patient perspective on symptom control (M. Mayer, US)
  • Disparities in access to supportive/palliative specialised care (N.S. El Saghir, LB)
  • Discussion
 18:00Novartis Oncology Reception
 18:30 Breast cancer patient advocacy - Meet the expert session
Where will we be in the coming years? (Chair: K. Redmond, CH; Panelists: L. Fallowfield, UK - L. Norton, US - A.H. Partridge, US - M.J. Piccart, BE )
 18:30-
 19:30
Novartis Oncology Satellite symposium
Advanced breast cancer cases - Packing for the journey
(Chair: W. Janni, DE)
 
  • Welcome aboard (W. Janni, DE)
  • Understanding the landscape of ABC (W. Janni, DE)
  • Mapping out treatment options in HR+/HER2- ABC 
    (G. Jerusalem, BE)
  • Maintaining quality of life and staying on course with therapy in HER+/HER2- ABC (M. Mano, BR)
  • Overall Q&A Panel
  • Conclusions and overview of the journeys ahead (W. Janni, DE).
 Symposium faculty

Wolfgang Janni, University of Ulm, Ulm, DE
Guy Jerusalem, Centre Hospitalier Universitaire, Liege, BE
Max Mano, University of Sao Paulo, Sao Paulo, BR

 

Saturday, 9 November

  9:00
13:00 

Exhibition

  9:00 

Consensus session (Part I)
(ABC2 Chairs)

10:30

Coffee break 

11:00

Report from ABC Patient Advocacy Committee
(
D.“CJ” M. Corneliussen-James, US)

11:15 Consensus session (Part II)
(ABC2 Chairs)

13:00 

Close



A/V RECORDING DURING THE CONFERENCE IS PROHIBITED 

 

Poster session

Posters can be viewed from Thursday, 7 November, 11:00 hours till Saturday, 9 November at 13:00 hours.
On Friday, 8 November, during the lunch break from 13:00 to 14:00 hours, the poster session will be held with the visit of the designated members of the faculty.

BP: Best poster presentation; PO: Poster presentation

 

 BP27  Count us, know us, join us global survey: Looking at quality of life issues affecting advanced breast cancer patients worldwide and the role of their caregivers. Shirley Mertz, US
 BP40  Multicenter phase II study of apatinib, a novel inhibitor of VEGFR, in heavily pretreated patients with metastatic triple negative breast cancer. Biyun Wang, CN
 BP41  Effectiveness of taxane- or anthracylin-based compared to taxane- and anthracyline-free first-line treatments of patients with metastatic breast cancer treated by German office-based medical oncologists. Data from the TMK Registry Group. Norbert Marschner, DE
 PO28  Defining the unique and persistent needs of young women in the U.S. living with metastatic breast cancer through a multi-phased needs assessment. Arin Hanson,US
 PO29  Metastatic breast cancer in Canada: The lived experience of patients and caregivers presented by the Canadian Breast Cancer Network. Niya Chari, CA
 PO30  Surveying young women with metastatic breast cancer to create interventions with impact. Jean Rowe, US
 PO31  Palliative care and metastatic breast cancer: Involvement of a community palliative care specialist nursing team. Maria Leadbeater, UK
 PO32  How do women with metastatic breast cancer view palliative care? A qualitative study using a grounded theory approach to enable the views of women to be sought. Tara Beaumont, UK
 PO33  Susan G. Komen® investment in metastatic breast cancer (MBC). Karen S. Durham, US 
 PO34   Funding priorities for cancer research in USA. An advocacy initiative to gauge perception of metastatic breast cancer research and funding amongst cancer researchers in the USA. Arti Santhanam, US                                        
 PO35  YSC research think tank:  Determining research priorities for young women with metastatic breast cancer. Jean Rowe, US
 PO36  Inflammatory breast cancer research foundation: Patient information and support, research collaboration and IBC bioBank. Ginny Mason, US
 PO37  Advanced breast cancer: Living in the moment. Never give up; even toward the end of life, a tiny flame of candle can give  still  warmth. Gloria Wei-Chieh Lin, TW
 PO38  A healthy walk with sticks in the midst of nature. Julia Lynn Fishwick, IT 
 PO42  Surgical management of primary tumor in newly diagnosed metastatic breast cancer patients - A systematic review of the literature. Felipe Ades, BE
 PO43  Role of breast surgery on survival of patients with primary advanced breast cancer. Iryna Liubota, UA
 PO44  Audit of the investigation and management of loco-regional breast cancer recurrences in a UK district general hospital. Alice Elvy, UK
 PO45  Surgical resection of the primary tumor may improve survival in patients with stage IV breast cancer. Kenji Higaki, JP    
 PO46     Pulmonary resection for lung oligometastatic disease in metastatic breast cancer. Mariko Kochi, JP
 PO47  Using local flaps for coverage of defects after excision of advanced malignant breast lesions. Mahmoud Alhussini, EG
 PO52    Are postchemotherapy target volume adequate as boost volume for conserved breast in locally advanced breast cancer? Sushma Agrawal, IN
 PO53    Clinical target volume in conserved breast in locally advanced breast cancer. Sushma Agrawal, IN
 PO54  Activity and duration of chemotherapy in different biologic subtypes in metastatic breast cancer patients. Matteo Lambertini, IT 
 PO55   The combination chemotherapy of gemcitabine and vinorelbine in HER2-negative patients with taxane-pretreated metastatic breast cancer: A phase II study of Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015 (UMIN000004839). Jun Yamamura, JP 
 PO56   Triple negative and hormone-negative/HER2-positive breast cancer: Which the worst for women with metastatic disease? A mono-institutional retrospective analysis on 460 patients. Raffaella Palumbo, IT
 PO57  Comparison of docetaxel plus trastuzumab and vinorelbine plus trastuzumab as first-line therapy of anthracycline pre-treated metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer (a sub-group analysis of the HERNATA study). Michael Andersson, DK   
 PO58  Efficacy and safety of first-line everolimus plus letrozole in ER+ HER2- metastatic breast cancer: A multi-center, open-label, phase 2 trial BOLERO-4. Francois Ringeisen, CH
 PO59  Efficacy and safety of everolimus plus exemestane combination therapy versus monotherapy with everolimus or capecitabine in HR+, HER2- breast cancer: A multi-center, open-label, phase 2 trial BOLERO-6. Guy Jerusalem, BE
 PO60  Good results of intensive systemic treatment of patients with HER2-positive breast cancer with brain metastases. Anna Niwinska, PL
 PO61  Oral vinorelbine and capecitabine: An acceptable and effective combination chemotherapy for early metastatic breast cancer (MBC). Martin Hogg, UK
 PO62  Different patterns of treatment with albumin-bounded paclitaxel (nab-paclitaxel) for targeted chemotherapy in metastatic breast cancer: A multicenter Italian experience on 125 women. Raffaella Palumbo, IT
 PO63  Impact of treatment with lapatinib in systemic advanced carcinoma breast. Manoj Behera, IN
 PO64  Comparison of fulvestrant versus tamoxifen for treatment advanced breast cancer in postmenopausal women. Charu Singh, IN
 PO65  The comparison of methotrexate and liposomal cytarabine in the  intrathecal treatment of patients with breast cancer and leptomeningeal metastasis. Anna Niwinska, PL
 PO66  All-oral combination chemotherapy with capecitabine and cyclophosphamide is effective and safe for metastatic breast cancer patients. Masahiko Suzuki, JP
 PO67  Clinical benefit of ethinylestradiol as a salvage endocrine therapy for the heavily pretreated-metastatic breast cancer. Hirotaka Iwase, JP
 PO68   Treatment with eribulin (Halaven) in heavily pre-treated patients with metastatic breast cancer. M Lynge, DK
 PO69  Eribulin in practice, review of 70 cases from single institute and comparison with Japan phase 2 study. Junichiro Watanabe, JP 
 PO70  Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to prior therapy. Carmine De Angelis, IT
 PO71   Safety profile and tolerability of trabectedin and indole-3-carbinol combination in refractory advanced breast cancer. Preliminary results of phase 1 clinical study. Richard Tancredi, IT 
 PO72  Clinical safety and efficacy of long-term use of zoledronic acid hydrate for breast cancer bone metastasis. Tomofumi Osako, JP  
 PO74  New trends in the survival of patients with locally advanced breast cancer. Nagi El Saghir, LB 
 PO75  Is the breast cancer graded prognostic assessment tool valid in Scottish patients with secondary brain metastases? Lucy Wells, UK
 PO76  Clinicopathological features and survival after recurrence in breast cancer patients with early and late recurrence after adjuvant chemotherapy. Byung Ho Son, KR
 PO77  Disease characteristics in HER2-positive metastatic breast cancer patients achieving complete remission during trastuzumab therapy. Snezana Susnjar, RS 
 PO79     Prolonged survival after breast cancer brain metastases (BCBM): Who has a chance? Zorica Tomasevic, RS
 PO80  Neutropenia may be a prediction marker of therapeutic effect in metastasis breast cancer patients treated with eribulin. Yuri Yoshimura, JP
 PO81  Electrochemotherapy of skin breast cancer metastases. Rodrigo Oom, PT
 PO82     Clinicopathological analysis of the risk factors of disease progression in HER2 positive breast cancer patients. Joanna Huszno, PL  
 PO83    Assessing acute thrombophlebitis due to intravenous vinorelbine chemotherapy in metastatic breast cancer patients at the University Hospital of North Staffordshire (UHNS). Shahid Gilani, UK 
 PO84  Visualizing treatment and outcomes in metastatic breast cancer. Gabrielle Rocque, USA  
 PO85  Characteristics and prognosis of hormone receptor positive and HER2 negative recurrent breast cancer patients receiving postoperative aromatase inhibitor. Ishida Mayumi, JP 
 PO86  Predictive markers of clinical outcome for breast cancer patients treated in phase 1 trials: National Cancer Center Hospital experience. Aiko Nagayama, JP
 PO87  Prognostic factors predicting survival after first recurrence in patients with metastatic breast cancer. Masahiro Hikichi, JP
 PO88  Locally advanced breast cancer in Albanian women. Elvisa Kozma, AL 
 PO89  Advanced breast cancer in Ethiopia: Characteristics and follow-up of 148 patients with stage 4 disease. Christoph Thomssen, DE  
 PO100  Long-term bone management by bisphosphonate in metastatic breast cancer patients. Junichiro Watanabe, JP 
 PO101  Management of peripheral neuropathy induced by nab-PTX therapy for breast cancer. Tsuyoshi Ohno, JP
 PO102  Paclitaxel induced CIPN - Can it be controlled? Rakesh Roy, IN
 PO103  Improving palliative care in clinical routine: Inhouse training of palliative medicine and its effects and evaluation in a breast and gynecological center of a CCC.  Rachel Wuerstlein, DE 
 PO104  Patients with discordance in estrogen receptor between primary breast cancers and recurrent tumors have poor outcomes. Sayuri Akiyoshi, JP 
 PO105  Changes in activities and participation resulting in disability associated with metastatic breast cancer. Ann Marie Potter, US
 PO106  Extended stability studies of anticancer drugs can improve the access of patients to innovative treatments. Example of eribulin in advanced/metastatic breast cancer. Alain Astier, FR
 PO107   Study of health resource utilisation in patients with HER2-positive metastatic breast cancer (SHRUB) – A prospective data collection study in progress. Jacinta Abraham, UK 
 PO108  Safety and efficacy of brachium implanted central venous access port for metastatic breast cancer patients. Tomomi Fujisawa, JP
 PO109  Use of whole body MRI in breast cancer: A retrospective analysis of WB-MRIs within a 12 month period in a cancer centre. Bhavi Trivedi, UK
 PO113  Discordance of hormone receptor and HER2 status between primary and recurrent breast cancer: New treatment strategy for predicting outcome of patients with breast cancer. Sho Shiino, JP
 PO115  Expression of androgen receptor in locally advanced breast cancer with special relation to various molecular phenotypes, clinicopathological factors and response to anterior chemotherapy in Indian women. Akshay Anand, IN
 PO116  Discordance in triple-receptor status between primary and recurrent breast cancer. Akiko Matsumoto, JP
 PO117  Impairment of IFN gamma production and NK cell cytotoxicity of advanced breast cancer patients. Sandra Radenkovic, RS  
 PO118  Significance of gene amplifications on relapse-free survival (RFS) and overall survival (OS) in metastatic breast cancer. Natasa Todorovic-Rakovic, RS 
 PO119  Immune reactivity at patient with breast cancer associated with type 2 diabetes mellitus. Natalia Botnariuc, MD 
 PO120  Factors, affecting changes in immunohistochemistry phenotype of breast cancer. Olexiy Aseyev, UA
 PO121  Increased relapse ratios in node-positive breast cancer patients with methylenetetrahydrofolate reductase polymorphism. Hakan Buyukhatipoglu, TR 
 PO122  Predictive factor of late recurrences in breast cancer patients. Hiromitsu Jinno, JP 
 PO123  Thymidylate synthase expression as a significant predictive factor in metastatic breast cancer. Hirohito Seki, JP 
 PO124  The influence of HER2 status on localization of the first relapse site in young HR-positive breast cancer patients treated with adjuvant ovarian ablation. Marijana Milovic-Kovacevic, RS 
 PO125  Influence of HER2 status on metastatic pattern in postmenopausal hormone receptor positive breast cancer patients treated with adjuvant tamoxifen only. Ivana Bozovic Spasojevic, RS

 

 

 

Consensus session 

 

The Panel will update the ABC consensus recommendations for the management of advanced breast cancer continuing the work developed during ABC1.
The ABC2 consensus manuscript will be published after the meeting.